Current Challenges and Future Perspectives of CAR-T Cell Therapy in Solid Tumors

Authors

  • Qixuan Gu College of Agriculture and Life Science, University of Wisconsin-Madison, Wisconsin, USA

DOI:

https://doi.org/10.54097/325p1w98

Keywords:

CAR-T therapy; Solid tumors; Tumor microenvironment (TME); Antigen heterogeneity.

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy has shown some good results. Clinical Success of Hematological Malignancies and its Efficacy in Solid Tumors. remains constrained. The various biological features of solid tumors are as follows: Heterogeneous antigen expression, poor tumour trafficking and invasion, etc. Immunosuppressive Tumor Microenvironment (TME) and T-cell Exhaustion. It will have little therapeutic effect for CAR-T cells. Although recent studies have shown some good results, these problems are still not fully resolved.This review summarizes the major barriers affecting CAR-T cell therapy in solid tumors and discusses recent advances aimed at overcoming these limitations. First of all, there is tumour antigen heterogeneity and antigen escape; Tumour homing is restricted, intratumoral penetration is poor, there is a suppressive tumour microenvironment, and T-cell function and dysfunction are gradually lost. Recently, some new treatment ideas have been put forward, such as multi-target CAR-T cells, modifications of the TME (tumor microenvironment), and gene-editing technology to construct next-generation CAR-T cells. In short, the above results show that in order to improve the efficacy of CAR-T therapy for solid tumors, many engineering strategies must be integrated to enhance tumour recognition, persistence and antitumor activity. Further progress will be made in cell engineering, gene editing and tumour immunology to advance the development of safer and more effective CAR-T therapy, providing new hope for the treatment of solid tumours.

Downloads

Download data is not yet available.

References

[1] Rosa R, Liu J, Lu C, Abou-El-Enein M, Murad JP, Priceman SJ. Current state of CAR-T cell therapies for solid tumors. Med. 2026 May 8;7(5):101028. doi: 10.1016/j.medj.2026.101028. Epub 2026 Feb 16. PMID: 41702407.

[2] Escobar G, Berger TR, Maus MV. CAR-T cells in solid tumors: Challenges and breakthroughs. Cell Rep Med. 2025 Nov 18;6(11):102353. doi: 10.1016/j.xcrm.2025.102353. Epub 2025 Sep 12. PMID: 40945517; PMCID: PMC12711667.

[3] Khan SH, Choi Y, Veena M, Lee JK, Shin DS. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors. Front Immunol. 2025 Jan 6; 15:1489827. doi: 10.3389/fimmu.2024.1489827. PMID: 39835140; PMCID: PMC11743624.

[4] Sterner RC, Sterner RM. CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 2021 Apr 1;11(4):69. doi: 10.1038/s41408-021-00459-7. PMID: 33795811; PMCID: PMC8017954.

[5] Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger T, D'Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016 Dec 29;375(26):2561-2569. doi: 10.1056/NEJMoa1610497. Epub 2016 Dec 19. PMID: 28029927; PMCID: PMC5390684.

[6] Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, Gad AZ, Janeway KA, Campbell M, Mullikin D, Nawas Z, Robertson C, Mathew PR, Zhang H, Mehta B, Bhat RR, Major A, Shree A, Gerken C, et al. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: A phase 1 trial. Nat Cancer. 2024 Jun;5(6):880-894. doi: 10.1038/s43018-024-00749-6. Epub 2024 May 13. PMID: 38740695; PMCID: PMC11120271.

[7] Haradhvala NJ, Leick MB, Maurer K, Mazzola E, Fernandez SP, Wu CJ, Ritz J, Chen YB, Fraietta JA. CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies. Nat Commun. 2023 Nov 30;14(1):8074. doi: 10.1038/s41467-023-43656-7. PMID: 38036584; PMCID: PMC10691290.

[8] Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, Ishiyama K, Wellhausen N, Rennels AK, Ma Y, Tian L, Guedan S, Alexander KA, Zhang Z, Rommel PC, Singh N, Glastad KM, Richardson MW, Watanabe K, et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell. 2021 Dec 9;184(25):6081-6100.e26. doi: 10.1016/j.cell.2021.11.016. Epub 2021 Nov 30. PMID: 34861176; PMCID: PMC8677606.

[9] Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ Jr, Riley JL, June CH, Albelda SM. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011 Jul 15;17(14):4719-4730. doi: 10.1158/1078-0432.CCR-11-0351. Epub 2011 May 24. PMID: 21610147; PMCID: PMC3142487.

[10] Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, Shen L, Wang Y. Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial interim results. Nat Med. 2022 Jun;28(6):1189-1198. doi: 10.1038/s41591-022-01800-8. Epub 2022 May 30. PMID: 35637483.

[11] Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Castro E, Melenhorst JJ, Plesa G, et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Mol Ther. 2019 Nov 6;27(11):1913-1922. doi: 10.1016/j.ymthe.2019.08.004. Epub 2019 Aug 29. PMID: 31474499; PMCID: PMC6839439.

[12] Smirnov S, Zaritsky Y, Silonov S, Gavrilova A, Fonin A. Advancing CAR-T therapy for solid tumors: From barriers to clinical progress. Biomolecules. 2025 Sep 30;15(10):1407. doi: 10.3390/biom15101407. PMID: 40558342; PMCID: PMC12531331.

Downloads

Published

15-11-2026

Issue

Section

Articles

How to Cite

Gu , Q. (2026). Current Challenges and Future Perspectives of CAR-T Cell Therapy in Solid Tumors. International Journal of Biology and Life Sciences, 17(2), 63-71. https://doi.org/10.54097/325p1w98